Literature DB >> 19090030

Five-year risk of colorectal neoplasia after negative colonoscopy.

Patrick Maisonneuve, Edoardo Botteri, Albert B Lowenfels.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 19090030

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial.

Authors:  Takuma Higurashi; Hirokazu Takahashi; Hiroki Endo; Kunihiro Hosono; Eiji Yamada; Hidenori Ohkubo; Eiji Sakai; Takashi Uchiyama; Yasuo Hata; Nobutaka Fujisawa; Shiori Uchiyama; Akiko Ezuka; Hajime Nagase; Takaomi Kessoku; Nobuyuki Matsuhashi; Shoji Yamanaka; Yoshiaki Inayama; Satoshi Morita; Atsushi Nakajima
Journal:  BMC Cancer       Date:  2012-03-26       Impact factor: 4.430

2.  Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF): a double-blind randomized controlled trial.

Authors:  Takuma Higurashi; Kunihiro Hosono; Hiroki Endo; Hirokazu Takahashi; Hiroshi Iida; Takashi Uchiyama; Akiko Ezuka; Shiori Uchiyama; Eiji Yamada; Hidenori Ohkubo; Eiji Sakai; Shin Maeda; Satoshi Morita; Yutaka Natsumeda; Hajime Nagase; Atsushi Nakajima
Journal:  BMC Cancer       Date:  2012-09-19       Impact factor: 4.430

3.  Inhibitory effect of metformin therapy on the incidence of colorectal advanced adenomas in patients with diabetes.

Authors:  Yo Han Kim; Ran Noh; Sun Young Cho; Seong Jun Park; Soung Min Jeon; Hyun Deok Shin; Suk Bae Kim; Jeong Eun Shin
Journal:  Intest Res       Date:  2015-04-27

Review 4.  Chemoprevention of colorectal cancer: Past, present, and future.

Authors:  Shotaro Umezawa; Takuma Higurashi; Yasuhiko Komiya; Jun Arimoto; Nobuyuki Horita; Takeshi Kaneko; Motoki Iwasaki; Hitoshi Nakagama; Atsushi Nakajima
Journal:  Cancer Sci       Date:  2019-09-17       Impact factor: 6.716

5.  The efficacy of a leukotriene receptor antagonist in the treatment of human rectal aberrant crypt foci: a nonrandomized, open-label, controlled trial.

Authors:  Takuma Higurashi; Jun Arimoto; Keiichi Ashikari; Tomohiro Takatsu; Noboru Misawa; Tsutomu Yoshihara; Tetsuya Matsuura; Akiko Fuyuki; Hidenori Ohkubo; Atsushi Nakajima
Journal:  BMC Cancer       Date:  2020-08-17       Impact factor: 4.430
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.